Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era

Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era

Bibliographic Details
Main Authors:	C. Cerchione, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137920301735

Similar Items

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
by: Anderson, L.D., Jr, et al.
Published: (2022)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Comparison of cyclophosphamide–thalidomide–dexamethasone to bortezomib–cyclophosphamide–dexamethasone as induction therapy for multiple myeloma patients in Brazil
by: Suelen Vigolo, et al.
Published: (2017-09-01)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
by: Albert Oriol, et al.
Published: (2021-05-01)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
by: Maria V. Mateos, et al.
Published: (2021-04-01)

Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
by: R Hada, et al.
Published: (2012-12-01)

Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
by: R Hada, et al.
Published: (2012-12-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-08-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
by: Shenghao Wu, et al.
Published: (2015-01-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021-06-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
by: Mohamad Mohty, et al.
Published: (2020-05-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib
by: Samer Alsidawi, et al.
Published: (2014-01-01)

Efficacy and safety of bortezomib with dexamethasone regimen in elderly newly diagnosed multiple myeloma patients with co-morbidities
by: Lee, Saem
Published: (2016)

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
by: Veronika Kodre, et al.
Published: (2008-04-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

RIBOMUSTINE (BENDAMUSTINE) IS APPROVED FOR THE TREATMENT IN MULTIPLE MYELOMA PATIENTS IN RUSSIA FEDERATION
by: - -
Published: (2013-12-01)

Bortezomib for the treatment of multiple myeloma patients
by: Green, Colin, et al.
Published: (2009)

Bortezomib for the treatment of multiple myeloma patients
by: C Green, et al.
Published: (2009-06-01)

Detection of BVD/MD
by: V. Wiwanitkit
Published: (2010-05-01)